Cue Biopharma Announces Strategic Organizational Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Cue Biopharma (CUE) PT Lowered to $4 at Jefferies
November 15, 2024 8:59 AM ESTJefferies analyst Maury Raycroft lowered the price target on Cue Biopharma (NASDAQ: CUE) to $4.00 (from $6.00) while maintaining a Buy rating.
The analyst comments "Stock has surged ~230% following CUE's recent $12M capital raise. However, the cash overhang still remains ($32M), limiting cos ability to... More



